Mark Wildgust, PhD, highlights results from the Phase 3 CASSIOPEIA study of daratumumab as maintenance therapy in first-line MM treatment after stem cell transplant, presented at the 2021 Annual ASH Meeting.

Mark Wildgust, PhD, reviews real-world evidence examining potential healthcare disparities- highlighting patient characteristics, treatment patterns and outcomes for Black and White patients with multiple myeloma who initiated treatment with daratumumab, presented at the 2021 Annual ASH Meeting.

Dr Williams Reviews SunRISe-2 Trial Results for Muscle-Invasive Urothelial Carcinoma by HMP Global

Charu Aggarwal, MD, Penn Medicine, Philadelphia, discusses incorporating plasma-based next-generation sequencing to improve guideline-concordant molecular testing in patients with newly diagnosed metastatic nonsquamous NSCLC.

Tapan M. Kadia, MD, highlights a phase 2 trial on venetoclax plus intensive chemotherapy in patients with newly diagnosed AML or MDS.

Ezzat Elhassadi, MD, Consultant Hematologist, University Hospital, Waterford, Ireland, discusses the impact of a p53 alteration in patients with mantle cell lymphoma (MCL); these data were presented at the EHA2021 Virtual Congress.

Aki Morikawa, MD, PhD, The University of Michigan, discusses assessing risk of brain metastasis in HER2+ breast cancer.

Jesus Berdeja, MD, shares findings from a phase 1 study of talquetamab therapy for relapsed/refractory MM. These data are being presented at the 2021 ASCO Annual Meeting.

Peter Martin, MD, talks about the various treatment patterns and outcomes of US patients with MCL over the past 10 years, the findings of which were presented at the 2021 ASCO Annual Meeting.

Dr Fakih Reviews Upfront Molecular Panel Testing in Metastatic GI Cancers by HMP Global